A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant.

Trial Profile

A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2018

At a glance

  • Drugs Rose bengal sodium (Primary)
  • Indications Liver cancer; Liver metastases; Uveal melanoma
  • Focus Adverse reactions
  • Sponsors Provectus Biopharmaceuticals
  • Most Recent Events

    • 31 Jul 2018 According to Provectus Biopharmaceuticals media release, the Company currently plans to present initial data from the metastatic uveal melanoma cohort at a medical conference in the second half of 2018, and also plans to present updated data from the entire basket study at a medical conference in the first half of 2019.
    • 31 Jul 2018 According to Provectus Biopharmaceuticals media release, new site for the basket study s new cohort is MD Anderson Cancer Center in Houston, Texas, and the principal investigator Sapna Patel, MD.
    • 31 Jul 2018 According to Provectus Biopharmaceuticals media release, has expanded to include a single-site cohort of 10 uveal melanoma patients with hepatic metastases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top